aspirin has been researched along with Invasiveness, Neoplasm in 32 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the expression of ATPase family AAA domain-containing protein 2 (ATAD2) and kinesin family member 4A (KIF4A) in esophageal squamous cell carcinoma (ESCC) tissues and their association with clinicopathological features and to explore the role of ATAD2 in regulating KIF4A expression and biological functions in ESCC cells and the effect of aspirin on their expression." | 8.12 | Aspirin Exerts Its Antitumor Effect in Esophageal Squamous Cell Carcinoma by Downregulating the Expression of ATAD2 and KIF4A. ( Liu, C; Liu, H; Ren, Z; Wang, X; Zhang, M; Zhao, J; Zheng, Z, 2022) |
| "Determine whether aspirin confers longer survival in patients with melanoma." | 7.88 | Postdiagnosis aspirin use and overall survival in patients with melanoma. ( Lautenschlaeger, T; Li, H; Li, Z; Rachidi, S; Wallace, K, 2018) |
| "Meta-analyses have demonstrated that low-dose aspirin reduces the risk of developing adenocarcinoma metastasis, and when colon cancer is detected during aspirin treatment, there is a remarkable 83% reduction in risk of metastasis." | 7.83 | Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. ( Adler, D; Amin, T; Boutaud, O; Crews, BC; Harris, BK; Hoeksema, M; Hwang, HS; Knollmann, BC; Lammers, PE; Marnett, LJ; Massion, PP; Milne, G; Oates, JA; Oram, D; Sosa, IR, 2016) |
| "Aspirin use has been associated with significant reductions in breast cancer-related mortality in some observational studies." | 7.81 | De Novo Post-Diagnosis Aspirin Use and Mortality in Women with Stage I-III Breast Cancer. ( Barron, TI; Bennett, K; Brown, C; Murphy, LM; Sharp, L; Visvanathan, K, 2015) |
| "The purpose of this study was to test the hypothesis that aspirin use is associated with a decreased risk of incident colorectal cancer." | 7.73 | The association between aspirin use and the incidence of colorectal cancer in women. ( Allison, M; Chlebowski, R; Criqui, M; Garland, C; Kuller, L; Langer, R; McTiernan, A; Roy, H; Wu, L, 2006) |
| "To investigate the expression of ATPase family AAA domain-containing protein 2 (ATAD2) and kinesin family member 4A (KIF4A) in esophageal squamous cell carcinoma (ESCC) tissues and their association with clinicopathological features and to explore the role of ATAD2 in regulating KIF4A expression and biological functions in ESCC cells and the effect of aspirin on their expression." | 4.12 | Aspirin Exerts Its Antitumor Effect in Esophageal Squamous Cell Carcinoma by Downregulating the Expression of ATAD2 and KIF4A. ( Liu, C; Liu, H; Ren, Z; Wang, X; Zhang, M; Zhao, J; Zheng, Z, 2022) |
| "Determine whether aspirin confers longer survival in patients with melanoma." | 3.88 | Postdiagnosis aspirin use and overall survival in patients with melanoma. ( Lautenschlaeger, T; Li, H; Li, Z; Rachidi, S; Wallace, K, 2018) |
| "Meta-analyses have demonstrated that low-dose aspirin reduces the risk of developing adenocarcinoma metastasis, and when colon cancer is detected during aspirin treatment, there is a remarkable 83% reduction in risk of metastasis." | 3.83 | Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. ( Adler, D; Amin, T; Boutaud, O; Crews, BC; Harris, BK; Hoeksema, M; Hwang, HS; Knollmann, BC; Lammers, PE; Marnett, LJ; Massion, PP; Milne, G; Oates, JA; Oram, D; Sosa, IR, 2016) |
| "Chronic inflammation is a risk factor for the onset of cancer and the regular use of aspirin reduces the risk of cancer development." | 3.83 | Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate. ( Brighenti, E; Derenzini, M; Fornari, F; Giannone, FA; Govoni, M; Montanaro, L; Onofrillo, C; Treré, D, 2016) |
| "Aspirin use has been associated with significant reductions in breast cancer-related mortality in some observational studies." | 3.81 | De Novo Post-Diagnosis Aspirin Use and Mortality in Women with Stage I-III Breast Cancer. ( Barron, TI; Bennett, K; Brown, C; Murphy, LM; Sharp, L; Visvanathan, K, 2015) |
| "The purpose of this study was to test the hypothesis that aspirin use is associated with a decreased risk of incident colorectal cancer." | 3.73 | The association between aspirin use and the incidence of colorectal cancer in women. ( Allison, M; Chlebowski, R; Criqui, M; Garland, C; Kuller, L; Langer, R; McTiernan, A; Roy, H; Wu, L, 2006) |
| "A protective effect on lung cancer or a benefit of higher doses of aspirin cannot be ruled out." | 2.71 | Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. ( Buring, JE; Cook, NR; Gaziano, JM; Gordon, D; Hennekens, CH; Lee, IM; Manson, JE; Ridker, PM, 2005) |
| "For example, cancer changes platelet behavior by directly inducing tumor-platelet aggregates, triggering platelet granule and extracellular vesicle release, altering platelet phenotype and platelet RNA profiles, and enhancing thrombopoiesis." | 2.58 | Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. ( Ni, H; Xu, XR; Yousef, GM, 2018) |
| "Further research on NSAIDs and ovarian cancer is needed before definite conclusions can be drawn." | 2.49 | Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. ( Andersen, KK; Baandrup, L; Christensen, J; Faber, MT; Friis, S; Jensen, A; Kjaer, SK, 2013) |
| "Oral squamous cell carcinoma (OSCC) is one of the most common cancers worldwide." | 1.48 | Aspirin is Involved in the Cell Cycle Arrest, Apoptosis, Cell Migration, and Invasion of Oral Squamous Cell Carcinoma. ( Feng, H; Guo, J; Li, M; Li, Z; Zhang, X, 2018) |
| "Aspirin has been demonstrated to possess potent chemopreventive and anticancer effects on prostate cancer." | 1.46 | Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator. ( Cao, J; Chen, X; Feng, Y; Liu, B; Shi, C; Zhang, N, 2017) |
| "It is unknown why different ovarian cancers have different metastatic phenotypes." | 1.42 | Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion. ( Cooke, NM; Kenny, D; O'Leary, J; Sheils, O; Spillane, CD, 2015) |
| "Accelerated progression of residual hepatocellular carcinoma (HCC) after incomplete radiofrequency ablation (RFA) has been reported more frequently." | 1.42 | Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation. ( Ding, J; Duan, B; Jiang, T; Lu, S; Zhang, X, 2015) |
| "He had been treated for lung cancer by chemotherapy and irradiation 3 years earlier." | 1.40 | [Case of cardiac tamponade during the treatment of acute cerebral infarction]. ( Nagasawa, H; Ono, H; Tanaka, H; Yamakawa, T, 2014) |
| "Invasive pancreatic cancer was identified in 15 of 25 (60%) LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre untreated control mice, but in only three of 17 (17." | 1.36 | The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. ( Bartsch, DK; Buchholz, M; Chen, NM; Feldmann, G; Fendrich, V; Maitra, A; Neef, M; Slater, EP; Waldmann, J, 2010) |
| "Treatment with aspirin or sodium salicylate inhibited invasiveness of the LMP1-expressing C33A cells (P < 0." | 1.31 | Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. ( Furukawa, M; Murono, S; Pagano, JS; Sato, H; Takeshita, H; Yoshizaki, T, 2000) |
| "Aspirin treatment also increased the production of the cell adhesion molecule, E-cadherin, in Hep G2 cancer cells." | 1.31 | Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. ( Jiang, MC; Lee, PH; Liao, CF, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 1 (3.13) | 18.2507 |
| 2000's | 11 (34.38) | 29.6817 |
| 2010's | 18 (56.25) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, M | 1 |
| Ren, Z | 1 |
| Wang, X | 1 |
| Liu, C | 1 |
| Zheng, Z | 1 |
| Zhao, J | 1 |
| Liu, H | 1 |
| Mohammed, A | 1 |
| Janakiram, NB | 1 |
| Madka, V | 1 |
| Zhang, Y | 1 |
| Singh, A | 1 |
| Biddick, L | 1 |
| Li, Q | 1 |
| Lightfoot, S | 1 |
| Steele, VE | 1 |
| Lubet, RA | 1 |
| Suen, CS | 1 |
| Miller, MS | 1 |
| Sei, S | 1 |
| Rao, CV | 1 |
| Rachidi, S | 1 |
| Wallace, K | 1 |
| Li, H | 1 |
| Lautenschlaeger, T | 1 |
| Li, Z | 2 |
| Xu, XR | 1 |
| Yousef, GM | 1 |
| Ni, H | 1 |
| Zhang, X | 2 |
| Feng, H | 1 |
| Guo, J | 1 |
| Li, M | 1 |
| Nagasawa, H | 1 |
| Ono, H | 1 |
| Tanaka, H | 1 |
| Yamakawa, T | 1 |
| Barron, TI | 1 |
| Murphy, LM | 1 |
| Brown, C | 1 |
| Bennett, K | 1 |
| Visvanathan, K | 1 |
| Sharp, L | 1 |
| Famenini, S | 1 |
| Duan, L | 1 |
| Young, L | 1 |
| Yang, H | 1 |
| Pellegrini, L | 1 |
| Napolitano, A | 1 |
| Giorgi, C | 1 |
| Jube, S | 1 |
| Preti, A | 1 |
| Jennings, CJ | 1 |
| De Marchis, F | 1 |
| Flores, EG | 1 |
| Larson, D | 1 |
| Pagano, I | 1 |
| Tanji, M | 1 |
| Powers, A | 1 |
| Kanodia, S | 1 |
| Gaudino, G | 1 |
| Pastorino, S | 1 |
| Pass, HI | 1 |
| Pinton, P | 1 |
| Bianchi, ME | 1 |
| Carbone, M | 1 |
| Franco, AT | 1 |
| Corken, A | 1 |
| Ware, J | 1 |
| Cooke, NM | 1 |
| Spillane, CD | 1 |
| Sheils, O | 1 |
| O'Leary, J | 1 |
| Kenny, D | 2 |
| Jiang, T | 1 |
| Ding, J | 1 |
| Duan, B | 1 |
| Lu, S | 1 |
| Singla, N | 1 |
| Haddad, AQ | 1 |
| Passoni, NM | 1 |
| Meissner, M | 1 |
| Lotan, Y | 1 |
| Boutaud, O | 1 |
| Sosa, IR | 1 |
| Amin, T | 1 |
| Oram, D | 1 |
| Adler, D | 1 |
| Hwang, HS | 1 |
| Crews, BC | 1 |
| Milne, G | 1 |
| Harris, BK | 1 |
| Hoeksema, M | 1 |
| Knollmann, BC | 1 |
| Lammers, PE | 1 |
| Marnett, LJ | 1 |
| Massion, PP | 1 |
| Oates, JA | 1 |
| Brighenti, E | 1 |
| Giannone, FA | 1 |
| Fornari, F | 1 |
| Onofrillo, C | 1 |
| Govoni, M | 1 |
| Montanaro, L | 1 |
| Treré, D | 1 |
| Derenzini, M | 1 |
| Shi, C | 1 |
| Zhang, N | 1 |
| Feng, Y | 1 |
| Cao, J | 1 |
| Chen, X | 1 |
| Liu, B | 1 |
| Tsai, CS | 1 |
| Luo, SF | 1 |
| Ning, CC | 1 |
| Lin, CL | 1 |
| Jiang, MC | 2 |
| Liao, CF | 2 |
| Fendrich, V | 1 |
| Chen, NM | 1 |
| Neef, M | 1 |
| Waldmann, J | 1 |
| Buchholz, M | 1 |
| Feldmann, G | 1 |
| Slater, EP | 1 |
| Maitra, A | 1 |
| Bartsch, DK | 1 |
| Arber, N | 1 |
| Spicak, J | 1 |
| Rácz, I | 1 |
| Zavoral, M | 1 |
| Breazna, A | 1 |
| Gerletti, P | 1 |
| Lechuga, MJ | 1 |
| Collins, N | 1 |
| Rosenstein, RB | 1 |
| Eagle, CJ | 1 |
| Levin, B | 1 |
| Baandrup, L | 1 |
| Faber, MT | 1 |
| Christensen, J | 1 |
| Jensen, A | 1 |
| Andersen, KK | 1 |
| Friis, S | 1 |
| Kjaer, SK | 1 |
| Lloyd, FP | 1 |
| Slivova, V | 1 |
| Valachovicova, T | 1 |
| Sliva, D | 1 |
| Ito, H | 1 |
| Duxbury, M | 1 |
| Benoit, E | 1 |
| Farivar, RS | 1 |
| Gardner-Thorpe, J | 1 |
| Zinner, MJ | 1 |
| Ashley, SW | 1 |
| Whang, EE | 1 |
| Lawler, K | 1 |
| Meade, G | 1 |
| O'Sullivan, G | 1 |
| Cook, NR | 1 |
| Lee, IM | 1 |
| Gaziano, JM | 1 |
| Gordon, D | 1 |
| Ridker, PM | 1 |
| Manson, JE | 1 |
| Hennekens, CH | 1 |
| Buring, JE | 1 |
| Allison, M | 1 |
| Garland, C | 1 |
| Chlebowski, R | 1 |
| Criqui, M | 1 |
| Langer, R | 1 |
| Wu, L | 1 |
| Roy, H | 1 |
| McTiernan, A | 1 |
| Kuller, L | 1 |
| Merritt, MA | 1 |
| Green, AC | 1 |
| Nagle, CM | 1 |
| Webb, PM | 1 |
| Viswanathan, AN | 1 |
| Feskanich, D | 1 |
| Schernhammer, ES | 1 |
| Hankinson, SE | 1 |
| Yamamoto, H | 1 |
| Itoh, F | 1 |
| Fukushima, H | 1 |
| Hinoda, Y | 1 |
| Imai, K | 1 |
| Murono, S | 1 |
| Yoshizaki, T | 1 |
| Sato, H | 1 |
| Takeshita, H | 1 |
| Furukawa, M | 1 |
| Pagano, JS | 1 |
| Lee, PH | 1 |
| Abiru, S | 1 |
| Nakao, K | 1 |
| Ichikawa, T | 1 |
| Migita, K | 1 |
| Shigeno, M | 1 |
| Sakamoto, M | 1 |
| Ishikawa, H | 1 |
| Hamasaki, K | 1 |
| Nakata, K | 1 |
| Eguchi, K | 1 |
| Bennett, A | 1 |
| Charlier, EM | 1 |
| McDonald, AM | 1 |
| Simpson, JS | 1 |
| Stamford, IF | 1 |
| Zebro, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
3 reviews available for aspirin and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents.
Topics: Aspirin; Blood Platelets; Cell Communication; Cell Proliferation; Extracellular Vesicles; Neoplasm I | 2018 |
Platelets at the interface of thrombosis, inflammation, and cancer.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cell Death; Cell Proliferation; Cell-Der | 2015 |
Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Confidence Intervals; Fem | 2013 |
2 trials available for aspirin and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.
Topics: Adenomatous Polyposis Coli; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Aspirin; Col | 2011 |
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.
Topics: Aspirin; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Human | 2005 |
27 other studies available for aspirin and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Aspirin Exerts Its Antitumor Effect in Esophageal Squamous Cell Carcinoma by Downregulating the Expression of ATAD2 and KIF4A.
Topics: Aspirin; ATPases Associated with Diverse Cellular Activities; Cell Line, Tumor; Cell Movement; Cell | 2022 |
Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma.
Topics: Adenocarcinoma; Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azoxymethane; Ca | 2019 |
Postdiagnosis aspirin use and overall survival in patients with melanoma.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Aspirin; Cohort Studies; Confidence Int | 2018 |
Aspirin is Involved in the Cell Cycle Arrest, Apoptosis, Cell Migration, and Invasion of Oral Squamous Cell Carcinoma.
Topics: Apoptosis; Aspirin; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movemen | 2018 |
[Case of cardiac tamponade during the treatment of acute cerebral infarction].
Topics: Acute Disease; Adenocarcinoma; Anterior Cerebral Artery; Antipyrine; Aspirin; Cardiac Tamponade; Cer | 2014 |
De Novo Post-Diagnosis Aspirin Use and Mortality in Women with Stage I-III Breast Cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Cyclooxygenas | 2015 |
Aspirin use and melanoma: A UCLA pilot study.
Topics: Academic Medical Centers; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy, Needle; C | 2015 |
Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression.
Topics: 3T3 Cells; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cell Li | 2015 |
Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
Topics: Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Line, Tumor; Female; Flow Cytometry; Humans; | 2015 |
Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Aspirin; Carcinoma, Hepatocellular; Cathet | 2015 |
Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2017 |
Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis.
Topics: Adenocarcinoma; Adult; Aspirin; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinop | 2016 |
Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line, Tumor; Epithelial-Mesenchymal | 2016 |
Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
Topics: Aspirin; Cell Line, Tumor; Humans; I-kappa B Kinase; Male; Matrix Metalloproteinase 9; Neoplasm Inva | 2017 |
Acetylsalicylic acid regulates MMP-2 activity and inhibits colorectal invasion of murine B16F0 melanoma cells in C57BL/6J mice: effects of prostaglandin F(2)alpha.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasm | 2009 |
The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
Topics: Amylases; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticarcinogenic Agents; Aspirin; Carci | 2010 |
Aspirin inhibits highly invasive prostate cancer cells.
Topics: Actins; Aspirin; Cell Adhesion; Cell Line, Tumor; Cell Movement; Chloramphenicol O-Acetyltransferase | 2003 |
Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Count; Cell Line, Tumor; Cells, Cultured; Cyc | 2004 |
Shear stress modulates the interaction of platelet-secreted matrix proteins with tumor cells through the integrin alphavbeta3.
Topics: Aspirin; Blood Platelets; Cell Adhesion; Cell Line, Tumor; Endothelium, Vascular; Extracellular Matr | 2004 |
The association between aspirin use and the incidence of colorectal cancer in women.
Topics: Aged; Aspirin; Chi-Square Distribution; Colorectal Neoplasms; Female; Humans; Incidence; Middle Aged | 2006 |
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anti-Inflammatory Age | 2008 |
Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cohort Stud | 2008 |
Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability.
Topics: Adaptor Proteins, Signal Transducing; Aspirin; Base Pair Mismatch; Carrier Proteins; Cyclooxygenase | 1999 |
Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression.
Topics: Animals; Aspirin; Blotting, Western; Cell Nucleus; Chloramphenicol O-Acetyltransferase; Enzyme Inhib | 2000 |
Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cadherins; Cell Movement; Cyclooxygenase Inhibitor | 2001 |
Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Cyclooxygenase 2; Cyclo | 2002 |
Prostaglandins and breast cancer.
Topics: Adolescent; Adult; Aged; Aspirin; Bone Neoplasms; Breast Neoplasms; Female; Humans; In Vitro Techniq | 1977 |